Najat Khan - 17 Feb 2026 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
CEO and President, Director
Signature
/s/ Kyle Nelson, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
17 Feb 2026
Net transactions value
-$49,837
Form type
4
Filing time
19 Feb 2026, 19:30:39 UTC
Previous filing
10 Feb 2026
Next filing
11 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Khan Najat CEO and President, Director 41 S. RIO GRANDE STREET, SALT LAKE CITY /s/ Kyle Nelson, attorney-in-fact 19 Feb 2026 0002020969

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Tax liability $49,837 -14,280 -0.62% $3.49 2,290,383 17 Feb 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.